Multicomponent Therapeutics

Polypharmacology in Drug Discovery

Volumn , Issue , 2012, Pages 315-321

  Borisy, Alexis A ^a   Zimmermann, Grant R ^b   Lehár, Joseph ^c  

^a THIRD ROCK VENTURES   (United States)

^b Zalicus Inc   (United States)

^c BOSTON UNIVERSITY   (United States)

Author keywords

Multicomponent therapeutics, context dependent; Synergistic therapies; Synergistic, antiinflammatory and therapeutic selectivity

Indexed keywords

EID: 84886053354     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118098141.ch15     Document Type: Chapter

References (17)

1. Hopkins, A. L. (2008), Network pharmacology: The next paradigm in drug discovery, Nature Chem. Biol. 4(11), 682-690.
2. Hughes, B. (2008), 2007 FDA drug approvals: A year of flux, Nature Rev. Drug Discov. 7 (2), 107-109.
3. Kitano, H. (2007), A robustness-based approach to systems-oriented drug design, Nature Rev. Drug Discov. 6(3), 202-210.
4. Keith, C. T.; Borisy, A. A.; Stockwell, B. R. (2005), Multicomponent therapeutics for networked systems, Nature Rev. Drug Discov. 4(1), 71-78.
5. Borisy, A. A.; Elliott, P. J.; Hurst, N.W.; Lee, M. S.; Lehár, J.; Price, E. R.; Serbedzija, G.; Zimmermann, G. R.; Foley, M. A.; Stockwell, B. R.; et al. (2003), Systematic discovery of multicomponent therapeutics, Proc. Natl. Acad. Sci. USA 100(13), 7977-7982.
6. Tong, A. H.; Lesage, G.; Bader, G. D.; Ding, H.; Xu, H.; Xin, X.; Young, J.; Berriz, G. F.; Brost, R. L.; Chang, M.; et al. (2004), Global mapping of the yeast genetic interaction network, Science 303(5659), 808-813.
7. Lehár, J.; Zimmermann, G. R.; Krueger, A. S.; Molnar, R. A.; Ledell, J. T.; Heilbut, A. M.; Short, G. F., 3rd; Giusti, L. C.; Nolan, G. P.; Magid, O. A.; et al. (2007), Chemical combination effects predict connectivity in biological systems, Mol. Syst. Biol. 3, 80.
8. Greco, W. R.; Bravo, G.; Parsons, J. C. (1995), The search for synergy: A critical review from a response surface perspective, Pharmacol. Rev. 47(2), 331-385.
9. Farr, M.; Bacon, P. A. (1995), How and when should combination therapy be used? The role of an anchor drug, Br. J. Rheumatol. 34 (Suppl. 2); 100-3.
10. Lehár, J.; Krueger, A. S.; Avery,W.; Heilbut, A. M.; Johansen, L. M.; Price, E. R.; Rickles, R. J.; Short, G. F., 3rd; Staunton, J. E.; Jin, X.; et al. (2009), Synergistic drug combinations tend to improve therapeutically relevant selectivity, Nature Biotechnol. 27(7), 659-666.
11. Duarte, N. C.; Herrgard, M. J.; Palsson, B. O. (2004), Reconstruction and validation of Saccharomyces cerevisiae iND750, a fully compartmentalized genome-scale metabolic model, Genome Res. 14(7), 1298-1309.
12. Qiu, Y. H.; Cheng, C.; Dai, L.; Peng, Y. P. (2005), Effect of endogenous catecholamines in lymphocytes on lymphocyte function, J. Neuroimmunol. 167(1-2), 45-52.
13. Su, A. I.;Wiltshire, T.; Batalov, S.; Lapp, H.; Ching, K. A.; Block, D.; Zhang, J. H.; Soden, R.; Hayakawa, M.; Kreiman, G.; et al. (2004), A gene atlas of the mouse and human protein-encoding transcriptomes, Proc. Natl. Acid. Sci. USA 101(16), 6062-6067.
14. Kvien, T. K.; Fjeld, E.; Slatkowsky-Christensen, B.; Nichols, M.; Zhang, Y.; Proven, A.; Mikkelsen, K.; Palm, O.; Borisy, A. A.; Lessem, J. (2007), Efficacy and safety of a novel synergistic drug candidate-CRx-102-in hand osteoarthritis, Ann. Rheum. Dis. 2008 Jul; 67(7):942-948. Epub 2007 Oct 25.
15. Zimmermann, G. R.; Avery, W.; Finelli, A. L.; Farwell, M.; Fraser, C. C.; Borisy, A. A. (2009), Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug, Arthritis Res. Ther. 11(1), R12.
16. Schäcke, H.; Rehwinkel, H.; Asadullah, K. (2005), Dissociated glucocorticoid receptor ligands: Compounds with an improved therapeutic index, Curr. Opin. Invest. Drugs 6(5), 503-507.
17. Lehár, J.; Krueger, A.; Zimmermann, G.; Borisy, A. (2008), High-order combination effects and biological robustness, Mol. Syst. Biol. 4, 215.